Single-arm TULSA study reports 12-month outcomes for localized prostate cancer
Phase 1-2 · BJU Int · 2026-11-10. Number 2 in the UrologyWatch Top 5 for November 10, 2026.
In a single-center phase II study of lesion-targeted transurethral ultrasound ablation in 59 men, 70% were free of in-field grade group 2+ cancer and 52% were free of prostate-wide grade group 2+ cancer at 12 months; no grade 3+ complications occurred within 3 months.
Why it matters: Adds early single-arm safety and efficacy data for a focal ablation technique in localized prostate cancer, but about half had residual clinically significant disease elsewhere in the gland.
Source: BJU Int · PubMed 43003389 · DOI 10.1111/bju.70531
Loading today's edition…